These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 7542357)

  • 21. Targeting of saporin to CD25-positive normal and neoplastic lymphocytes by an anti-saporin/anti-CD25 bispecific monoclonal antibody: in vitro evaluation.
    Tazzari PL; Zhang S; Chen Q; Sforzini S; Bolognesi A; Stirpe F; Xie H; Moretta A; Ferrini S
    Br J Cancer; 1993 Jun; 67(6):1248-53. PubMed ID: 8512810
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CD19- and anti-CD38-saporin immunotoxins used in combination than with either immunotoxin used alone.
    Flavell DJ; Boehm DA; Emery L; Noss A; Ramsay A; Flavell SU
    Int J Cancer; 1995 Jul; 62(3):337-44. PubMed ID: 7543082
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma.
    Messmann RA; Vitetta ES; Headlee D; Senderowicz AM; Figg WD; Schindler J; Michiel DF; Creekmore S; Steinberg SM; Kohler D; Jaffe ES; Stetler-Stevenson M; Chen H; Ghetie V; Sausville EA
    Clin Cancer Res; 2000 Apr; 6(4):1302-13. PubMed ID: 10778955
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bispecific monoclonal antibodies for the targeting of type I ribosome-inactivating proteins against hematological malignancies.
    Ferrini S; Sforzini S; Canevari S
    Methods Mol Biol; 2001; 166():177-92. PubMed ID: 11217367
    [No Abstract]   [Full Text] [Related]  

  • 25. A comparison of anti-lymphocyte immunotoxins containing different ribosome-inactivating proteins and antibodies.
    Bolognesi A; Tazzari PL; Tassi C; Gromo G; Gobbi M; Stirpe F
    Clin Exp Immunol; 1992 Sep; 89(3):341-6. PubMed ID: 1516253
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Saporin, a ribosome-inactivating protein used to prepare immunotoxins, induces cell death via apoptosis.
    Bergamaschi G; Perfetti V; Tonon L; Novella A; Lucotti C; Danova M; Glennie MJ; Merlini G; Cazzola M
    Br J Haematol; 1996 Jun; 93(4):789-94. PubMed ID: 8703804
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotoxins containing saporin linked to different CD2 monoclonal antibodies: in vitro evaluation.
    Tazzari PL; Bolognesi A; De Totero D; Lemoli RM; Fortuna A; Conte R; Crumpton MJ; Stirpe F
    Br J Haematol; 1994 Jan; 86(1):97-105. PubMed ID: 7912101
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single tumor cell uptake and dosimetry of technetium-99m Fab' or minute anti-CD22 in low-grade B-cell lymphoma.
    Lindén O; Hindorf C; Tennvall J; Segrén S; Wingardh K; Strand SE
    Cancer; 2002 Feb; 94(4 Suppl):1270-4. PubMed ID: 11877756
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotoxins containing saporin 6 and monoclonal antibodies recognizing plasma cell-associated antigens: effects on target cells and on normal myeloid precursors (CFU-GM).
    Barbieri L; Dinota A; Gobbi M; Tazzari PL; Rizzi S; Bontadini A; Lemoli RM; Tura S; Stirpe F
    Eur J Haematol; 1989 Mar; 42(3):238-45. PubMed ID: 2784390
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.
    Ghetie MA; May RD; Till M; Uhr JW; Ghetie V; Knowles PP; Relf M; Brown A; Wallace PM; Janossy G
    Cancer Res; 1988 May; 48(9):2610-7. PubMed ID: 2451562
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin.
    Senderowicz AM; Vitetta E; Headlee D; Ghetie V; Uhr JW; Figg WD; Lush RM; Stetler-Stevenson M; Kershaw G; Kingma DW; Jaffe ES; Sausville EA
    Ann Intern Med; 1997 Jun; 126(11):882-5. PubMed ID: 9163289
    [No Abstract]   [Full Text] [Related]  

  • 32. A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy.
    Amlot PL; Stone MJ; Cunningham D; Fay J; Newman J; Collins R; May R; McCarthy M; Richardson J; Ghetie V
    Blood; 1993 Nov; 82(9):2624-33. PubMed ID: 8219217
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents.
    Newton DL; Hansen HJ; Liu H; Ruby D; Iordanov MS; Magun BE; Goldenberg DM; Rybak SM
    Crit Rev Oncol Hematol; 2001; 39(1-2):79-86. PubMed ID: 11418304
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotoxins containing recombinant anti-CTLA-4 single-chain fragment variable antibodies and saporin: in vitro results and in vivo effects in an acute rejection model.
    Tazzari PL; Polito L; Bolognesi A; Pistillo MP; Capanni P; Palmisano GL; Lemoli RM; Curti A; Biancone L; Camussi G; Conte R; Ferrara GB; Stirpe F
    J Immunol; 2001 Oct; 167(8):4222-9. PubMed ID: 11591743
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapy of human T-cell acute lymphoblastic leukaemia in severe combined immunodeficient mice with two different anti-CD7-saporin immunotoxins containing hindered or non-hindered disulphide cross-linkers.
    Flavell DJ; Boehm DA; Okayama K; Kohler JA; Flavell SU
    Int J Cancer; 1994 Aug; 58(3):407-14. PubMed ID: 7519586
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intra-thecal treatment of leptomeningeal lymphoma with immunotoxin.
    Urch CE; George AJ; Stevenson GT; Bolognesi A; Stirpe F; Weller R; Glennie MJ
    Int J Cancer; 1991 Apr; 47(6):909-15. PubMed ID: 2010234
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 67Ga citrate versus 99mTc-labeled LL2-Fab' (anti-CD22) fragments in the staging of B-cell non-Hodgkin's lymphoma.
    Becker WS; Behr TM; Cumme F; Rössler W; Wendler J; Kern PM; Gramatzki M; Kalden JR; Goldenberg DM; Wolf FG
    Cancer Res; 1995 Dec; 55(23 Suppl):5771s-5773s. PubMed ID: 7493344
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin.
    Falini B; Bolognesi A; Flenghi L; Tazzari PL; Broe MK; Stein H; Dürkop H; Aversa F; Corneli P; Pizzolo G
    Lancet; 1992 May; 339(8803):1195-6. PubMed ID: 1349939
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting of type 1 ribosome-inactivating proteins to CD30+ or CD25+ hematologic neoplasias by bispecific antibodies.
    Sforzini S; Bolognesi A; Meazza R; Marciano S; Tazzari PL; Stein H; Stirpe F; Ferrini S
    J Hematother; 1995 Oct; 4(5):429-32. PubMed ID: 8581380
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recognition and killing of tumour cells expressing heat shock protein 65 kD with immunotoxins containing saporin.
    Poccia F; Piselli P; Di Cesare S; Bach S; Colizzi V; Mattei M; Bolognesi A; Stirpe F
    Br J Cancer; 1992 Sep; 66(3):427-32. PubMed ID: 1520580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.